Shiraz E-Medical Journal
The addition of ribavirin (RIBA) to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monotherapy to 40-45% in combination therapy. The aim of this study is to assess the therapeutic efficacy and safety of IFN alpha (PDferon) in combination with RIBA on Iranian patients with chronic hepatitis C (CHC).
48 naive patients aged 18 years or more with CHC were enrolled and treated with 3 mega units (MU) IFN ?-2b three times a week plus 600-1000 mg RIBA per day for 48 weeks. Follow-up after therapy was 6 months. The efficacy was evident at the end of treatment and at the end of follow-up in terms of sustained normalization of alanine aminotransferase and sustained serum HCV-RNA loss.
The rate of sustained biochemical and virologic response were 68.3% and 78%, respectively. 40 patients (83.3%) had at least one not serious complication and 8 patients (16.7%) didnt have any complication. Any patient didnt have serious complication.
Although we had no control group who used standard IFN, our preliminary finding showed acceptable and promising response rate of PDferon. On the other hand, it seems that adverse events with PDferon are as like as other standard IFNs.
© 2006, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:
Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:
Alavian SM, Ahmadzad Asl M, keshvari M, Behnava B, hajibeigi B. Efficacy and safety of Interferon-alpha (PDferon B®) and Ribavirin Combination Therapy in patients with Chronic Hepatitis C in Iran. Hepat Mon. 2006;6(1):e92946. doi:
Sali S, Ahmadzad Asl M, Alavian SM, Sali S, Ahmadzad Asl M, et al. Interferon –alpha 2b (PDferon B®) in Treatment of HBeAgnegative Chronic Hepatitis B; Preliminary Report. Hepat Mon. 2004;4(6):e92938. doi:
Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
